Observational studyBMC neurology2026
Treatment patterns and adverse events of antiseizure medications among adult patients with epilepsy: a single centre observational cross-sectional study in Northern Sri Lanka.
Observational study in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntiseizure medications (ASMs) are essential for seizure control, but they are also associated with a range of adverse events that may affect treatment outcomes.
objectiveThis study aimed to evaluate the treatment pattern and adverse events of ASMs among adult patients with epilepsy who were followed up at a tertiary-care hospital in Northern Sri Lanka.
methodsA descriptive cross-sectional study was conducted among adult patients on ASMs for ≥ 3 months who were receiving follow-up at Teaching Hospital Jaffna. Data were collected over four months using a pretested interviewer-administered questionnaire. Chi-square test and logistic regression were performed to determine the significance between groups and the association of independent variables, respectively. A p-value of ≤ 0.05 was considered statistically significant.
resultsData from 213 participants was analysed. The mean age was 36.27 ± 0.92 years, and the male-to-female ratio was almost 1. Nearly two-thirds of participants (64.8%) were on dual or polytherapy. Older ASMs were predominantly prescribed (74.5%). A total of 333 adverse events were reported, giving a point prevalence of 68.5% and a rate of 1.6 adverse events per person. Sedation (27%), memory impairment (24%), and dizziness (21%) were the most common adverse events. Advancing age (adjusted OR (AOR): 4.3, 95% CI 1.87 to 10.29, p < 0.001), early onset of epilepsy (AOR: 0.35, 95% CI 0.14 to 0.87, p = 0.023), and the use of multiple ASMs (AOR: 2.7, 95% CI 1.4 to 5.3, p = 0.003) were associated with the occurrence of adverse events. Carbamazepine, clobazam and valproic acid were significantly (p < 0.05) associated with one or more common adverse events.
conclusionMost patients in this study received older antiseizure medications and polytherapy. A high burden of adverse events linked to antiseizure medications was also observed. Studies with larger samples are needed to determine the safety and efficacy of current practices and to plan treatment strategies to optimise the epilepsy care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.